![]() | Clinical UM Guideline |
Subject: Drug Testing or Screening in the Context of Substance Use Disorder and Chronic Pain | |
Guideline #: CG-LAB-09 | Publish Date: 01/03/2024 |
Status: Reviewed | Last Review Date: 11/09/2023 |
Description |
This document addresses the use of drug testing (using urine, blood, saliva, sweat or hair) in the outpatient setting for adherence monitoring in the following situations:
Note: This document does not address the use of urine drug testing in the following circumstances:
Note: Drug testing or screening for employment issues may be addressed in the member certificate. Please refer to the member’s benefits for further information.
Note: Sample validation is a method that is sometimes needed to assure source integrity. Quality assurance to assure sample integrity is part of expected clinical laboratory test management.
Note: For more information about pain biomarker urine testing, please see:
Clinical Indications |
Medically Necessary:
Presumptive urine drug testing (UDT) to verify compliance with treatment, identify undisclosed drug use or abuse, or evaluate aberrant* behavior is considered medically necessary up to 24 times per year, beginning at the start of treatment, as part of a monitoring program tailored to the unique needs of individuals who are:
Presumptive urine drug testing is also considered medically necessary for the following:
Definitive urine drug testing to verify compliance with treatment, identify undisclosed drug use or abuse, or evaluate aberrant* behavior is considered medically necessary up to 24 times per year, beginning at the start of treatment, as part of a monitoring program tailored to the unique needs of individuals whose requests meet criteria both A and B below:
*Aberrant behavior includes, but is not limited to, lost prescriptions, repeated requests for early refills, prescriptions from multiple providers, unauthorized dose escalation, and apparent intoxication.
Note: Each definitive test request must be based on the tested individual’s diagnosis, substance use patterns, results of presumptive testing and other clinical factors documented in the medical record. Community patterns of illicit drug use must not be imputed to an individual without a documented rationale. UDT monitoring of prescribed drugs is not a clinically appropriate way to estimate the therapeutic effectiveness of prescribed drugs. Definitive testing for more than 7 classes of drugs (including metabolites) would be unusual for most individuals. For a list of drug classes, see the Appendix below.
The use of blood samples as an alternative to urine for drug testing is considered medically necessary when the use of urine is not feasible (for example, when an individual has advanced kidney failure).
Not Medically Necessary:
The use of presumptive urine drug testing is considered not medically necessary when the criteria above are not met.
The use of definitive urine drug testing is considered not medically necessary when the criteria above are not met.
The use of presumptive or definitive testing panels is considered not medically necessary unless all components of the panel have been determined to be medically necessary based on the criteria above. However, individual components of a panel may be considered medically necessary when criteria above are met.
The use of blood samples for drug testing is considered not medically necessary in all other circumstances, including when the criteria above have not been met.
The use of saliva, sweat, or hair samples for drug testing is considered not medically necessary in all circumstances.
The use of any of the following for definitive drug testing of urine or blood samples is considered not medically necessary in all circumstances:
Coding |
The following codes for treatments and procedures applicable to this guideline are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.
When services may be Medically Necessary when criteria are met:
CPT |
|
| Presumptive Drug Class Screening codes: |
80305 | Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; capable of being read by direct optical observation only (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]) includes sample validation when performed, per date of service |
80306 | Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; read by instrument assisted direct optical observation (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when performed, per date of service |
80307 | Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service |
|
|
| Definitive Drug Testing codes: |
80320 | Alcohols |
80321 | Alcohol biomarkers; 1 or 2 |
80322 | Alcohol biomarkers; 3 or more |
80323 | Alkaloids, not otherwise specified |
80324 | Amphetamines; 1 or 2 |
80325 | Amphetamines; 3 or 4 |
80326 | Amphetamines; 5 or more |
80327 | Anabolic steroids; 1 or 2 |
80328 | Anabolic steroids; 3 or more |
80329 | Analgesics, non-opioid, 1 or 2 |
80330 | Analgesics, non-opioid, 3-5 |
80331 | Analgesics, non-opioid, 6 or more |
80332 | Antidepressants, serotonergic class; 1 or 2 |
80333 | Antidepressants, serotonergic class; 3-5 |
80334 | Antidepressants, serotonergic class; 6 or more |
80335 | Antidepressants, tricyclic and other cyclicals; 1 or 2 |
80336 | Antidepressants, tricyclic and other cyclicals; 3-5 |
80337 | Antidepressants, tricyclic and other cyclicals; 6 or more |
80338 | Antidepressants, not otherwise specified |
80339 | Antiepileptics, not otherwise specified; 1-3 |
80340 | Antiepileptics, not otherwise specified; 4-6 |
80341 | Antiepileptics, not otherwise specified; 7 or more |
80342 | Antipsychotics, not otherwise specified; 1-3 |
80343 | Antipsychotics, not otherwise specified; 4-6 |
80344 | Antipsychotics, not otherwise specified; 7 or more |
80345 | Barbiturates |
80346 | Benzodiazepines; 1-12 |
80347 | Benzodiazepines; 13 or more |
80348 | Buprenorphine |
80349 | Cannabinoids, natural |
80350 | Cannabinoids, synthetic; 1-3 |
80351 | Cannabinoids, synthetic; 4-6 |
80352 | Cannabinoids, synthetic; 7 or more |
80353 | Cocaine |
80354 | Fentanyl |
80355 | Gabapentin, non-blood |
80356 | Heroin metabolite |
80357 | Ketamine and norketamine |
80358 | Methadone |
80359 | Methylenedioxyamphetamines |
80360 | Methylphenidate |
80361 | Opiates, 1 or more |
80362 | Opioids and opiate analogs; 1 or 2 |
80363 | Opioids and opiate analogs; 3 or 4 |
80364 | Opioids and opiate analogs; 5 or more |
80365 | Oxycodone |
80366 | Pregabalin |
80368 | Sedative hypnotics (non-benzodiazepines) |
80369 | Skeletal muscle relaxants; 1 or 2 |
80370 | Skeletal muscle relaxants; 3 or more |
80371 | Stimulants, synthetic |
80372 | Tapentadol |
80373 | Tramadol |
80374 | Stereoisomer (enantiomer) analysis, single drug class |
80375 | Drug(s) or substance(s), definitive, qualitative or quantitative, not otherwise specified; 1-3 |
80376 | Drug(s) or substance(s), definitive, qualitative or quantitative, not otherwise specified; 4-6 |
80377 | Drug(s) or substance(s), definitive, qualitative or quantitative, not otherwise specified; 7 or more |
83992 | Phencyclidine (PCP) |
0328U | Drug assay, definitive, 120 or more drugs and metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS), includes specimen validity and algorithmic analysis describing drug or metabolite and presence or absence of risks for a significant patient adverse event, per date of service |
|
|
HCPCS |
|
G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays [e.g., IA, EIA, ELISA, EMIT, FPIA] and enzymatic methods [e.g., alcohol dehydrogenase]), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day, 1-7 drug class(es), including metabolite(s) if performed |
G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays [e.g., IA, EIA, ELISA, EMIT, FPIA] and enzymatic methods [e.g., alcohol dehydrogenase]), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day, 8-14 drug class(es), including metabolite(s) if performed |
G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays [e.g., IA, EIA, ELISA, EMIT, FPIA] and enzymatic methods [e.g., alcohol dehydrogenase]), stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day, 15-21 drug class(es), including metabolite(s) if performed |
G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays [e.g., IA, EIA, ELISA, EMIT, FPIA] and enzymatic methods [e.g., alcohol dehydrogenase]), stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day, 22 or more drug class(es), including metabolite(s) if performed |
G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem), excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes |
|
|
ICD-10 Diagnosis |
|
| All diagnoses |
When services are Not Medically Necessary:
For the procedure codes listed above when criteria are not met or for situations designated in the Clinical Indications section as not medically necessary.
When services are also Not Medically Necessary:
For the following procedure codes, or when the code describes a procedure designated in the Clinical Indications section as not medically necessary.
CPT |
|
0011U | Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, using oral fluid, reported as a comparison to an estimated steady-state range, per date of service including all drug compounds and metabolites |
0082U | Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions per date of service |
0093U | Prescription drug monitoring, evaluation of 65 common drugs by LC-MS/MS, urine, each drug reported detected or not detected |
0116U | Prescription drug monitoring, enzyme immunoassay of 35 or more drugs confirmed with LC-MS/MS, oral fluid, algorithm results reported as a patient-compliance measurement with risk of drug to drug interactions for prescribed medications |
0227U | Drug assay, presumptive, 30 or more drugs or metabolites, urine, liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, includes sample validation |
|
|
HCPCS |
|
P2031 | Hair analysis (excluding arsenic) |
|
|
ICD-10 Diagnosis |
|
| All diagnoses |
Discussion/General Information |
Urine Drug Testing (UDT)
The use of UDT in individuals with a substance use disorder or undergoing opioid treatment for chronic pain conditions is common and serves several purposes. According to the American College of Physicians (ACP, 2008), the reasons for UDT include:
The American Pain Society (APS) and American Academy of Pain Medicine (AAPM) joint guidelines panel released their opioid treatment guidelines titled Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Non-cancer Pain in 2009 (Chou, 2009). In this document, the AAPM addressed the monitoring of controlled substances use via UDT as part of a chronic opioid treatment (COT) program. The guideline section on monitoring (Section 5) states:
5.1 Clinicians should reassess patients on COT periodically and as warranted by changing circumstances. Monitoring should include documentation of pain intensity and level of functioning, assessments of progress toward achieving therapeutic goals, presence of adverse events, and adherence to prescribed therapies (strong recommendation, low-quality evidence).
5.2 In patients on COT who are at high risk or who have engaged in aberrant drug-related behaviors, clinicians should periodically obtain urine drug screens or other information to confirm adherence to the COT plan of care (strong recommendation, low-quality evidence).
5.3 In patients on COT not at high risk and not known to have engaged in aberrant drug-related behaviors, clinicians should consider periodically obtaining urine drug screens or other information to confirm adherence to the COT plan of care (weak recommendation, low-quality evidence). Clinicians should periodically reassess all patients on COT. Regular monitoring of patients once COT is initiated is critical because therapeutic risks and benefits do not remain static.
In 2017, the American Society of Addition Medicine (ASAM) published a document titled Appropriate Use of Drug Testing in Clinical Addiction Medicine (Jarvis, 2017). The ASAM provided an array of recommendations related to UDT and other drug testing procedures. The document included the following recommendations regarding presumptive and definitive testing:
The ASAM document also addressed testing frequency:
Finally, ASAM recommended the following related to UDT:
*Point of care tests.
In 2019 ASAM published a document titled Public Policy Statement on the Ethical Use of Drug Testing in the Practice of Addiction Medicine. This document contained important statements regarding the ethical use of drug testing, including:
The exact frequency and pattern of urine drug screening is individualized based on the risk for abuse. The Washington State Agency Medical Directors' Group (AMGD) published an Interagency Guideline on opioid dosing for pain. This guideline and related expert commentary support low-risk individuals having 1 UDTs up to once per year, moderate-risk up to 2 UDTs per year, high-risk individuals up to 3-4 UDTs per year. Individuals exhibiting aberrant behaviors should be tested at the time of the office visit. The American Pain Society guidelines (Chou, 2009) state that for individuals at low risk for adverse outcomes, quarterly or semi-annual monitoring is sufficient. For very high-risk individuals, weekly monitoring may be reasonable. However, the AMGD states that there is insufficient evidence to support this recommendation. This observation is reiterated in a review article by McMillin and colleagues (2013), where they comment that there is a lack of detailed guidelines addressing the appropriate use of DUT to support chronic pain management. The ASAM white paper does not recommend an upper limit for testing. However, in the context of abuse, the McMillin review recommends testing no less than once weekly at first then once monthly once abstinence is established. Such limits apply to both presumptive and definitive testing. There is insufficient clinical reasoning to support the use of definitive testing at a frequency greater than for presumptive testing.
The American College of Obstetricians and Gynecologists (ACOG) recommends a screening interview for substance use be completed on the first prenatal visit as part of comprehensive obstetric care (2017). ACOG recommends following up with UDT to detect or confirm suspected substance use when the individual consents.
The risk for abuse may be measured using standard tools, such as the Screener and Opioid Assessment for Patients with Pain (SOAPP®; PainEdu.org, 2013) and the Revised Opioid Risk Tool (ORT-R or ORT-OUD; Cheatle, 2019). These tools aid clinicians in assessing the suitability of long-term opioid therapy for individuals with chronic pain, and help differentiate those who may require more or less clinician monitoring while on long-term opioid therapy. The SOAPP tool is available for free and can be accessed at https://www.mcstap.com/docs/SOAPP-5.pdf . Four different versions are available to allow for varying levels of evaluation. All versions of the SOAPP tool may be self-administered at or prior to an office visit or can be completed as part of an interview with a nurse, physician or psychologist. The ORT was developed by Webster (2005) and was modified by Cheatle in 2019 (ORT-R/ORT-OUD). Like the SOAPP, it may be self-administered or used as part of a clinical evaluation. The ORT-R/ORT-OUD can be accessed for free at https://nida.nih.gov/nidamed-medical-health-professionals/screening-tools-resources/opioid-risk-tool-oud-ort-oud.
Presumptive versus Definitive Testing
Presumptive testing is intended to identify the use or non-use of a drug or class of drugs. Definitive tests are more specific and allow for the detection of specific drugs or metabolites of interest. In most cases presumptive testing is used because it is quick, fairly accurate, and easily accessible in a wide variety of settings. Definitive testing may be needed when presumptive results alone are not sufficient to guide clinical care. However, in most situations, the identification or quantification of a specific drug of interest may not result in a different treatment plan. Definitive testing, particularly when performed repeatedly, must be clinically meaningful and documentation must support the specific necessity of each definitive assay performed as well as how that test result will affect clinical management.
Drug Testing of Blood, Saliva, Sweat, or Hair Samples
The 2017 ASAM recommendations (Jarvis, 2017) address the use of alternate sample matrices in the following statements:
These recommendations support the use of oral fluid testing for presumptive detection; however, the evidence cited in the guideline discussion consists of low-quality references including reviews and a study that evaluates the volume of oral fluid needed for an appropriate sample. The recommendations reference a Committee Opinion from the American College of Obstetricians and Gynecologists (ACOG) on ethical issues in relation to alcohol abuse and other substance use disorders. ACOG recommends routine screening with validated questionnaires or conversations and does not recommend routine laboratory testing of biologic samples for substance use disorders (ACOG, 2015). ASAM does suggest that oral fluid testing might be useful in some cases, but further research on which specific drugs and metabolites oral fluid testing might best detect is recommended (Jarvis, 2017).
The U.S. Department of Health and Human Services (DHHS) Substance Abuse and Mental Health Services Administration (SAMHSA) has published two documents that address drug testing for individuals in primary care and substance abuse disorder treatment programs (SAMHSA, 2012, 2014). In these documents, the benefits and drawbacks of drug testing using alternative sample sources is evaluated. However, in their primary care document (2012) SAMHSA clarifies that urine is the most widely used and studied source. This was reiterated in their 2014 Treatment Improvement Protocol (TIP) for opioid addiction programs.
The use of samples other than urine, including blood, hair, saliva, and sweat, is not recommended by most authoritative organizations that provide guidance on drug testing, including the ACP (Kirschner, 2014), the American Pain Society (APS) and the American Academy of Pain Medicine (AAPM, Chou, 2010) and the Washington State Agency Medical Directors' Group (AMGD, 2015). The American Society of Transplantation recommends urine drug testing in individuals when needed to identify abuse and diversion and to guide treatment (Jowsey-Gregoire, 2022). The use of UDT is not possible in some circumstances. Individuals with renal failure who are on dialysis or those with bladder control impairments may be unable to provide a sample. In these limited circumstances, UDT may need to be replaced by blood tests.
There is growing support for the use of saliva testing, especially in cases where a urine sample is unobtainable, when such results may be unreliable, or when there is a history of urine sample tampering. However, as noted above, there is little evidentiary support for this approach.
In summary, the use of blood, hair, saliva, and sweat is not widely recommended and these matrices each have significant drawbacks to their use when compared to UDT.
Testing Panels
Many commercial laboratories market multi-test panels for the presence of various prescription and illicit drugs and their metabolites. While the use of some individual tests included in these test panels may be reasonable under specific circumstances, the use of all the tests within a panel is rarely justified unless there is clinical evidence that an individual has used or been exposed to multiple substances, and knowledge of such exposure provides information that leads to meaningful impact on treatment.
Reflex testing, Standing orders, and Blanket orders
The use of reflex testing, standing orders, and blanket orders for definitive testing of urine or blood samples is contrary to good clinical practice, which is based on clinical decision-making as to the necessity of specific laboratory tests. In the case of these types of tests, they are done in the absence of the requisite clinical decision-making process and are based solely on automated processes devoid of clinical judgment. They do not meet the requirement for there to be documentation of a specific rationale for each ordered test and documentation of how the test will be used to modify treatment for the tested individual.
Definitions |
Blanket order: A test request that is not for a specific individual, but it is an identical order for all individuals in a clinician’s practice. Such orders do not take the clinical situation of each individual into consideration at the time of request, or during each visit.
Definitive testing: A type of testing that is more specific than presumptive testing, and allows for the detection of specific drugs or metabolites.
Drug class: Drugs, medications or illicit substances (including metabolites of each member of the class) that share similar essential aspects of their chemical structure and at least one similar mechanism of action (i.e., bind to the same biological target). For example, opioids interact with one or more opioid receptor. Drugs associated with substance use disorders, including alcohol and inhalants, are thought to directly activate the brain reward system as a common mode of action.
Drug diversion: Prescription drugs provided to an individual other than the one to whom the drugs were prescribed.
Drug testing panel: A type of test that involves tests for more than one type of drug and may test for a pre-defined set of drug classes or metabolites of specific drugs or drug classes.
Member-specific profile: This term refers to the specific characteristics of an individual being treated for chronic pain or an individual undergoing treatment for opioid addiction and substance use disorder, which may be used to help guide treatment. These characteristics may include current and past alcohol and drug use patterns and clinical findings such as slurred speech, hallucinations or pin-point pupils that tend to be specific to a drug or drug class. Use of member-specific profiles assist in guiding the selection of the specific tests for drugs and their metabolites.
Planned testing: Testing being conducted at a time previously scheduled and known to the individual being tested.
Presumptive testing: A type of testing that is intended to identify the use or non-use of a drug or general class of drugs.
Random testing: Testing being conducted at a time not previously scheduled and not known to the individual being tested.
Reflex Testing: A laboratory test that is performed "reflexively" after an initial or presumptive test result suggests the need for further diagnostic information. This type of testing is not based on a specific clinical situation and provider's order, but is built into the testing process. Testing performed as a step necessary to complete the request of physician responsible for a members care and provided by an order is not considered reflex testing.
Standing order: A test request for a specific individual representing: 1) repetitive testing to monitor a condition or disease, or 2) individualized orders for repetitive automatic testing for certain individuals for pre-determined tests based on historical use, risk, and community trend patient profiles. Definitive drug testing standing orders are not consistent with ordering laboratory testing based upon clinical findings, nor are they sensitive to the individual’s history of drug use and community patterns of drug use.
Testing panel: A type of laboratory procedure where multiple tests are automatically run on a single sample to detect the presence of a variety of substances or class of substances.
References |
Peer Reviewed Publications:
Government Agency, Medical Society, and Other Authoritative Publications:
Index |
Buprenorphine
Naloxone
Suboxone®
The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.
History |
Status | Date | Action |
Reviewed | 11/09/2023 | Medical Policy & Technology Assessment Committee (MPTAC) review. Updated Discussion/General Information and References section. |
| 06/28/2023 | Updated Coding section with 07/01/2023 CPT changes; removed 0143U, 0144U, 0145U, 0146U, 0147U, 0148U, 0149U, 0150U, codes deleted as of 07/01/2023. |
Reviewed | 11/10/2022 | MPTAC review. Updated Description, Discussion and References section. |
| 06/29/2022 | Updated Coding section with 07/01/2022 CPT changes; added 0328U. |
Reviewed | 11/11/2021 | MPTAC review. Updated Discussion and References section. |
| 01/07/2021 | Corrected date error in History section. |
Reviewed | 11/05/2020 | MPTAC review. Updated Reference sections. Reformatted Coding section and updated with 01/01/2021 CPT changes, added PLA code 0227U. |
Revised | 05/14/2020 | MPTAC review. Revised note in Clinical Indications section in relation to drug classes. Added Appendix section with drug class table. Updated Rationale and References sections. Updated Coding section; added codes 80329, 80330, 80331. |
| 04/01/2020 | Updated Coding section with 04/01/2020 CPT changes; removed 0006U deleted 03/31/2020. |
Reviewed | 11/07/2019 | MPTAC review. Updated Rationale and References sections. Updated Coding section with 01/01/2020 CPT changes; added codes 0143U, 0144U, 0145U, 0146U, 0147U, 0148U, 0149U, 0150U. |
| 10/01/2019 | Updated Coding section with 10/01/2019 CPT changes; added 0116U, revised descriptor for 0082U. |
| 06/27/2019 | Updated Coding section with 07/01/2019 CPT changes; added 0093U. |
Revised | 01/24/2019 | MPTAC review. Clarified MN statement for presumptive testing. Expanded MN statement regarding definitive testing. Added note regarding number of drug classes tested for during definitive testing. Updated Rationale and References sections. |
| 12/27/2018 | Updated Coding section with 01/01/2019 CPT changes; added 0082U. |
| 06/28/2018 | Updated Coding section with 07/01/2018 CPT changes; revised descriptor for code 0006U. |
Reviewed | 03/22/2018 | MPTAC review. |
Reviewed | 02/23/2018 | Behavioral Health Subcommittee review. Updated References section. |
| 12/27/2017 | The document header wording updated from “Current Effective Date” to “Publish Date.” Updated Coding section with 01/01/2018 CPT descriptor changes for codes 80305-80307. |
Revised | 08/03/2017 | MPTAC review. |
Revised | 07/21/2017 | Behavioral Health Subcommittee review. Updated formatting in Clinical Indications section. Added new NMN statement regarding reflex testing, standing orders, and blanket orders. Updated Description, Discussion, and References sections. Updated Coding section with 08/01/2017 CPT changes; added 0006U and 0011U. |
| 01/01/2017 | Updated Coding section with 01/01/2017 CPT and HCPCS changes; removed codes 80300, 80301, 80302, 80303, 80304, G0477, G0478, G0479 deleted 12/31/2016. |
Reviewed | 08/04/2016 | MPTAC review. |
Reviewed | 07/29/2016 | Behavioral Health Subcommittee review. Updated Discussion and References sections. |
Revised | 02/04/2016 | MPTAC review. |
Revised | 01/29/2016 | Behavioral Health Subcommittee review. Revised title to change “Substance Abuse” to “Substance Use Disorder”. Added the use of blood, saliva, sweat, or hair to position statement. Revised Background, Coding and References sections. |
| 01/01/2016 | Updated Coding section with 01/01/2016 HCPCS changes, removed codes G0431, G0434, G6031, G6040, G6041, G6042, G6043, G6044, G6045, G6046, G6048, G6051, G6052, G6053, G6056, G6057, G6058 deleted 12/31/2015; also removed ICD-9 codes. |
Revised | 02/05/2015 | MPTAC review. |
Revised | 01/30/2015 | Behavioral Health Subcommittee review. Revised clinical indications section to address “presumptive” and “definitive” testing. Clarified the limit of 24 tests per calendar year to be a rolling 24 year. Updated Discussion, Definitions, and References sections. |
| 01/01/2015 | Updated Coding section with 01/01/2015 CPT and HCPCS changes; removed deleted codes and codes 80184, 82491, 82492, 82541, 82542, 82543, 82544 (no longer applicable). |
Revised | 02/13/2014 | MPTAC review. |
Revised | 02/07/2014 | Behavioral Health Subcommittee review. Added not medically necessary statement addressing the use of testing panels. Updated Discussion, Definitions, and References sections. |
New | 11/14/2013 | MPTAC review. Initial document development. |
Appendix |
The following table lists drugs and their metabolites in drug classes based on Generic Product Index level 2 classifications (GPI2), the FDA’s National Drug Classifications (NDC), PubChem classifications, and the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), but does not include every drug and metabolite. Metabolites not listed in the table should be categorized with their parent drug.
Drug Class | Drugs and Metabolites
| Reference
|
Alcohols | Ethyl Glucuronide | PubChem |
Ethyl Sulfate | PubChem | |
ETOH | PubChem | |
Methanol | PubChem | |
Analgesics, NonNarcotic | Acetaminophen | GPI2, PubChem |
Diclofenac | DSM-5, NDC | |
Ibuprofen | DSM-5, NDC | |
Ketoprofen | DSM-5, NDC | |
Naproxen | DSM-5, NDC | |
Androgens, Anabolic | Anabolic Steroids | PubChem |
Clostebol | PubChem | |
Danazol | GPI2, PubChem | |
Methyltestosterone | GPI2, PubChem, NDC | |
Anticonvulsants | Carbamazepine | GPI2, PubChem, NDC |
Cannabidiol | GPI2, PubChem | |
Gabapentin | GPI2, PubChem | |
Lamotrigine | GPI2, PubChem, NDC | |
Phenytoin | GPI2, PubChem, NDC | |
Pregabalin | GPI2, PubChem | |
Primidone | GPI2, PubChem | |
Topiramate | GPI2, PubChem, NDC | |
Valproic Acid | GPI2, PubChem | |
Zonisamide | GPI2, PubChem | |
Antidepressants | Amitriptyline | GPI2, PubChem, NDC |
Amoxapine | GPI2, PubChem | |
Bupropion | GPI2, PubChem, NDC | |
Citalopram | GPI2, PubChem | |
Desipramine | GPI2, PubChem, NDC | |
Desvenlafaxine | GPI2, PubChem, NDC | |
Doxepin | GPI2, PubChem, NDC | |
Duloxetine | GPI2, PubChem, NDC | |
Fluvoxamine | GPI2, PubChem | |
Fluoxetine | GPI2, PubChem | |
Escitalopram | GPI2, PubChem, NDC | |
Imipramine | GPI2, PubChem, NDC | |
Mirtazapine | GPI2, PubChem | |
Nefazodone | GPI2, PubChem | |
Nortriptyline | GPI2, PubChem, NDC | |
Paroxetine | GPI2, PubChem, NDC | |
Phenelzine | GPI2, PubChem | |
Selegiline | PubChem, NDC | |
Sertraline | GPI2, PubChem, NDC | |
Tranylcypromine | GPI2, PubChem, NDC | |
Trazodone | GPI2, PubChem, NDC | |
Venlafaxine | GPI2, PubChem, NDC | |
Vilazodone | GPI2, PubChem | |
Vortioxetine | GPI2, PubChem | |
Antipsychotics/Antimanic Agents | Aripiprazole | GPI2, PubChem, NDC |
Cariprazine | GPI2, PubChem | |
Chlorpromazine | GPI2, PubChem, NDC | |
Clozapine | GPI2, PubChem, NDC | |
Haloperidol | GPI2, PubChem, NDC | |
Lurasidone | GPI2, PubChem | |
Olanzapine | GPI2, PubChem, NDC | |
Paliperidone | GPI2, PubChem, NDC | |
Perphenazine | GPI2, PubChem, NDC | |
Risperidone | GPI2, PubChem, NDC | |
Thioridazine | GPI2, PubChem, NDC | |
Ziprasidone | GPI2, PubChem, NDC | |
Barbiturates and Barbituate-Like Drugs | Amobarbital | GPI2, PubChem, DSM-5 |
Butabarbital | GPI2, PubChem, DSM-5 | |
Butalbital | DSM-5, PubChem, NDC | |
Glutethimide | DSM-5, PubChem | |
Meprobamate | DSM-5, PubChem | |
Pentobarbital | GPI2, PubChem, DSM-5 | |
Phenobarbital | GPI2, PubChem, DSM-5 | |
Secobarbital | GPI2, PubChem, DSM-5 | |
Benzodiazepine and Benzodiazepine-Like Drugs | Alprazolam | GPI2, PubChem, DSM-5, NDC |
Chlordiazepoxide | GPI2, PubChem, DSM-5, NDC | |
Clonazepam | GPI2, PubChem, DSM-5, NDC | |
Clorazepate | GPI2, PubChem, DSM-5 | |
Diazepam | GPI2, PubChem, DSM-5, NDC | |
Eszopiclone | GPI2, PubChem, DSM-5 | |
Flumazenil | GPI2, PubChem, DSM-5, NDC | |
Lorazepam | DSM-5, PubChem, NDC | |
Oxazepam | GPI2, PubChem, DSM-5 | |
Temazepam | GPI2, PubChem, DSM-5, NDC | |
Zaleplon | GPI2, PubChem, DSM-5 | |
Zolpidem | DSM-5, PubChem | |
Cannabinoids | Dronabinol | PubChem |
K2/Spice | PubChem | |
Marijuana | DSM-5 | |
Marinol | PubChem | |
THC | PubChem | |
Cathinones | Bath salts | DSM-5, PubChem |
Kratom | DSM-5, PubChem | |
Hallucinogen-Related Disorders, Other Hallucinogen Use Disorder | Atropine | PubChem |
Dimethyltryptamine (DMT) | DSM-5, PubChem | |
DOM | DSM-5, PubChem | |
Jimson weed | DSM-5, PubChem | |
LSD (Ergolines) | DSM-5, PubChem | |
Mescaline (Phenylalkylamines) | DSM-5, PubChem | |
MDA | DSM-5, PubChem | |
MDEA | DSM-5, PubChem | |
MDMA | DSM-5, PubChem | |
Morning Glory Seeds | DSM-5, PubChem | |
Phenethylamine | PubChem | |
Psilocybin (Indoleamines) | DSM-5, PubChem | |
Salvia Divinorum | DSM-5, PubChem | |
Salvinorin | PubChem | |
Scopolamine | PubChem | |
Hallucinogen-Related Disorders, Phencyclidine Use Disorder | Phencyclidine | DSM-5, PubChem |
Ketamine (Including Esketamine) | DSM-5, PubChem | |
Cyclohexamine (1-Phenylcyclohexylamine) | DSM-5, PubChem | |
Dizocilpine | DSM-5, PubChem | |
Norketamine | PubChem | |
Musculoskeletal Therapy Agents | Baclofen | GPI2, PubChem |
Carisoprodol | GPI2, PubChem, NDC | |
Cyclobenzaprine | GPI2, PubChem, NDC | |
Metaxalone | GPI2, PubChem | |
Methocarbamol | GPI2, PubChem, NDC | |
Orphenadrine | GPI2, PubChem, NDC | |
Tizanidine | GPI2, PubChem | |
Opioids | 6-Acetylmorphine (6-MAM) | PubChem |
Acetylcodeine | PubChem | |
Acetylfentanyl | PubChem | |
Actiq | GPI2, PubChem | |
Alfentanil | GPI2, PubChem, NDC | |
Belbuca | GPI2, PubChem | |
Bunavail | GPI2, PubChem | |
Buprenorphine (for example, Subutex and others) | GPI2, PubChem, NDC | |
Butorphanol | GPI2, PubChem, NDC | |
Butrans | GPI2, PubChem | |
Codeine | GPI2, PubChem, NDC | |
Desomorphine | PubChem | |
Dextromethorphan | PubChem | |
Dextrophan | PubChem | |
Diacetylmorphine (commonly known as heroin) | PubChem | |
Diamorphine (commonly known as heroin) | PubChem | |
Dihydrocodeine | GPI2, PubChem, NDC | |
EDDP | PubChem | |
Fentanyl | GPI2, PubChem | |
Heroin | PubChem | |
Hydrocodone | GPI2, PubChem, NDC | |
Hydromorphone | GPI2, PubChem, NDC | |
Kratom | PubChem | |
Levorphanol | GPI2, PubChem | |
Meperidine | GPI2, PubChem, NDC | |
Methadone | GPI2, PubChem, NDC | |
Mitragynine | PubChem | |
Morphine | GPI2, PubChem, NDC | |
Naloxone | GPI2, PubChem, NDC | |
Naltrexone | GPI2, PubChem, NDC | |
Norfentanyl | PubChem | |
Noroxycodone | PubChem | |
Norpropoxyphene | PubChem | |
O-Desmethyltramadol | PubChem | |
Oxycodone | GPI2, PubChem, NDC | |
Oxymorphone | GPI2, PubChem, NDC | |
Pentazocine | GPI2, PubChem, NDC | |
Probuphine | GPI2, PubChem, NDC | |
Propoxyphene | GPI2, PubChem | |
Sublocade | GPI2, PubChem | |
Suboxone | GPI2, PubChem | |
Subutex | PubChem | |
Sufentanil | PubChem | |
Tapentadol | GPI2, PubChem | |
Tramadol | GPI2, PubChem, NDC | |
Ultram | GPI2, PubChem, NDC | |
Zubsolv | GPI2, PubChem, NDC | |
Other Drugs or Metabolites | Drugs or Metabolites Not Otherwise Specified | N/A |
Other (or Unknown) Substance Use Disorder | Cortisol | DSM-5 |
Nitrous Oxide (“Laughing Gas”) | DSM-5 | |
Amyl-, Butyl, Isobutyl-Nitrites | DSM-5 | |
Betel Nut | DSM-5 | |
Kava | DSM-5 | |
Stimulants, Amphetamine-Type Substance | Amphetamine | DSM-5, PubChem, NDC |
D/L Isomer Analysis | DSM-5, PubChem | |
Dextroamphetamine | DSM-5, PubChem, NDC | |
Lisdexamfetamine | DSM-5, PubChem | |
Methamphetamine | DSM-5, PubChem, NDC | |
Methylphenidate | DSM-5, PubChem, NDC | |
Phentermine | DSM-5, PubChem, NDC | |
Phenylpropanolamine | DSM-5, PubChem | |
Pseudoephedrine | PubChem | |
Ritalinic Acid | PubChem | |
Stimulants, Cocaine | Benzoylecgonine | DSM-5, PubChem |
Cocaine | DSM-5, PubChem | |
Ecgonine Methyl Ester | DSM-5, PubChem | |
Tobacco Use Disorder | Cotinine | DSM-5, PubChem |
Nicotine | DSM-5, PubChem |
Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.
No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.
© CPT Only – American Medical Association